ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Avara advances in dosage form business with third buy

by Rick Mullin
June 3, 2018 | APPEARED IN VOLUME 96, ISSUE 23

 

The contract development and manufacturing firm Avara Pharmaceuticals has agreed to acquire Novartis’s sterile production facility for injectable medicines and the adjacent Sandoz Development Center in Boucherville, Quebec. The agreement follows acquisitions over the past year of a Pfizer sterile drug facility in Licate, Italy, and a GlaxoSmithKline solid-dose production site in Aiken, S.C. Avara anticipates no impact on jobs at the Boucherville site, which it calls the largest facility of its type in Canada.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment